Disappearance of symptomatic venous thrombosis after neonatal cardiac operations during antithrombin III substitution  by Petäjä, Jari et al.
Venous thrombosis (VT) of the central intrathoracic veins
is a significant complication after cardiac operations.1 In
neonates, secondary antithrombin III (AT III) deficiency is
one component of a complicated postoperative coagulopathy
contributing to the thrombogenesis.2-4 We previously sug-
gested that substitution therapy with AT III concentrate might
be a viable approach to reducing the incidence of VT.2
Accordingly, we now report our experience after 3 years of
applying a systematic AT III substitution policy in postoper-
ative neonatal care. It seems that AT III substitution helps to
avoid symptomatic VT.
Patients and methods 
AT III substitution policy. Since March 1995, systematic
daily follow-up of plasma AT III levels was recommended in
the Children’s Hospital, University of Helsinki, during the
postoperative intensive care of neonates who have undergone
cardiac operations. Likewise, substitution with AT III con-
centrate (Atenative, Pharmacia & Upjohn, Finland) for levels
below 50% of the adult mean was encouraged. The dose was
calculated on the basis of the AT III level but was typically
about 50 IU/kg, with the aim of a postinfusion AT III level
between 80% and 100%. However, the decision to both mea-
sure AT III and prescribe the substitute was left to the anes-
thesiologist responsible for the particular patient. The result
was 90% coverage of eligible patients (see below) and minor
variation in the AT III levels used as the indication for AT III
substitution.
Historical controls. The control group consisted of 160
neonates who underwent cardiac operations between January
1985 and February 1995.
Study cohort. Between March 1995 and June 1998, 102
neonates underwent a cardiac operation. During this period,
an active operative approach was also applied to patients with
severe hypoplastic left heart syndrome. Eleven such patients
died during the immediate perioperative period before first
postoperative AT III measurement, and these patients were
excluded from the study cohort. An additional group of 9 sur-
viving patients was excluded from the study because AT III
was not measured during the postoperative intensive care
period. The study cohort thus consisted of 82 neonates.
Phlebography was performed if symptoms of venous stasis
were suspected. The right atrium was repeatedly visualized in
routine postoperative cardiac echocardiograms.
Results. The plasma AT III level was measured 455 times
in the study cohort. The AT III level was below 41% of the
adult mean (lower limit of normal for neonates)5 in 47 (57%),
14 (17%), and 14 (17%) during postoperative days 1 to 3, 4
to 6, and 7 to 10, respectively. Using the 50% cutoff for sec-
ondary AT III deficiency, the frequencies were 68 (83%), 33
(40%), and 24 (29%) during postoperative days 1 to 3, 4 to 6,
and 7 to 10, respectively. Sixty-eight (83%) patients received
a total of 62,965 IU of AT III concentrate (mean ± standard
deviation 768 ± 119 IU per cohort patient) (Fig 1).
In the historical controls, 10 of the 160 neonates had central
VT as described in detail earlier1 (Table I). In all 10 patients, VT
was considered clinically significant according to the following
criteria: (1) VT caused (n = 1) or significantly contributed (n =
3) to the death of the patient. (2) The patient survived, but VT
caused symptoms of superior vena cava syndrome (n = 3). (3)
On the basis of the judgment of the physician responsible, the
extent and location of VT necessitated thrombolytic treatment
(n = 3). The thrombi were diagnosed during the 10 years as fol-
lows: 1988, n = 2; 1990, n = l; 1992, n = l; 1993, n = 3; 1994, n
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Fig 1. The administration of antithrombin III (AT III) con-
centrate in the cohort of 82 neonates undergoing cardiac
operations. On the basis of plasma AT III determinations, 14
patients did not receive AT III concentrate. Sixty-one percent
of the cumulative dose was given between postoperative days
1 and 5. Day 0 indicates the day of operation.
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= 2; 1995, n = l. The overall postoperative mortality was 22
deaths (15%) among 150 patients without VT and 4 deaths
(40%) among 10 patients with VT.
In the study cohort, no symptomatic VT was observed
(Table I). Within this cohort the overall postoperative mortal-
ity was 14 deaths (17%) among 82 patients.
In a patient with transposition of the great arteries (TGA)
and the arterial switch operation, a small mural thrombus in
the right atrium was observed by echocardiography on post-
operative day 14. No treatment was considered necessary, and
the patient made an uneventful recovery. Despite AT III sub-
stitution, however, the patient had an AT III level below 51%
on 7 occasions between postoperative days 1 and 9. In anoth-
er patient undergoing arterial switch for TGA, the postopera-
tive course was first complicated by cardiac tamponade after
removal of a catheter from the left pulmonary artery on post-
operative day 3. After the resternotomy, the patient had signs
of a septic infection. On postoperative day 9, his condition
deteriorated and an abdominal catastrophe was suspected.
Strangulation of the small intestine was discovered at laparo-
tomy. Extensive intestinal resection was performed, but imme-
diately after the operation his hemodynamic condition deteri-
orated and the patient died. An autopsy showed severe damage
to the remaining gut, and changes consistent with ischemic
multiorgan failure were also evident in the kidneys and liver.
The abdominal arterial and venous circulations were free of
thrombi. A fresh, short VT was discovered in the superior vena
cava. It was concluded that the patient died of the intestinal
catastrophe unrelated to the VT. Despite AT III substitution,
plasma AT III was below 51% on 5 occasions between post-
operative days 1 and 7. The lowest AT III level in this patient
was 18% on postoperative day 4, even though he received an
83 IU/kg dose of AT III concentrate on day 3.
Discussion. AT III substitution for secondary postoperative
AT III deficiency in neonatal cardiac operations was associat-
ed with abrupt disappearance of symptomatic VT. Our rea-
sons for undertaking this practice were multiple. First, previ-
ous work showed that neonates had up to a 10-fold risk of VT
compared with older children undergoing cardiac opera-
tions.1 Second, thrombogenesis in this patient group was
associated with multiple prothrombotic alterations in coagu-
lation, including a transient AT III deficiency preceding
symptomatic VT.2 Third, little could be done to reduce the
thrombogenic burden caused by indwelling catheters, surgi-
cal trauma, and postoperative hemodynamic changes.
Research proof of both efficacy and safety of alternative VT
prophylaxis by heparin or oral anticoagulants in neonates is
also lacking. Finally, AT III substitution was feasible because
of the transient nature of postoperative AT III decrease and
the availability of a virus-inactivated concentrate.
In the absence of observed AT III–induced bleeding com-
plications, cost-benefit becomes a central issue. At Finnish
prices for AT III concentrate and AT III determinations, the
estimated cost of the AT III substitution for the study cohort
was $40,000 (US currency). The figures in Table I show that
this should be compared with the estimated benefit of avoid-
ing 5 clinically significant VTs. Since $8000 (US currency)
per avoided VT corresponds to the cost of 4 to 5 days of
intensive care, we believe that AT III substitution for the
cohort of 82 neonates was medically beneficial in a cost-neu-
tral way.
Since the current study was neither randomized nor blind-
ed, several possible biases exist, but for certain central issues
bias is unlikely. First, since all neonatal cardiac operations in
Finland are performed at the Children’s Hospital, there is no
patient selection bias. If anything, more moribund patients
like those with severe hypoplastic left heart syndrome have
recently been included. Second, no major changes in the per-
fusion techniques or the perfusion team have taken place
since 1995. Finally, no significant changes concerning the
types and care (including heparinization of the infused solu-
tions) of central venous catheters have taken place during the
1990s. Thus we hope that our observational data and experi-
ence prove sufficiently provocative to stimulate randomized
VT prophylaxis studies in neonatal cardiac surgery.
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Table I. Antithrombin III (AT III) substitution in
neonates undergoing cardiac operations
AT III 
Before substitution P value
VT 10/160 (6.3%) 2*/82 (2.3%) .20
Clinically significant VT† 10/160 (6.3%) 0/82 (0%) .021
VT-associated mortality 4/160 (2.5%) 0/82 (0%) .15
Before indicates operations carried out before March 1995, when AT III sub-
stitution was not used, and AT III substitution indicates the operations during
the AT III substitution policy as explained in the “Patients and methods.”
*Both patients with asymptomatic VT had plasma AT III levels below 51% of
the adult mean on several days preceding the detection of VT despite AT III
substitution.
†For definition of “Clinically significant VT” see text. The P value was calcu-
lated by the c 2 test (1-tailed). 
